Disseminated Intravascular Coagulation in Sepsis and Associated Factors
Abstract
:1. Introduction
2. Method
3. Inclusion and Exclusion Criteria
4. Variables
5. Statistical Analysis
6. Result
7. Discussion
8. Study Limitation
9. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801–810. [Google Scholar] [CrossRef] [PubMed]
- Marik, P.E.; Taeb, A.M. SIRS, qSOFA and new sepsis definition. J. Thorac. Dis. 2017, 9, 943–945. [Google Scholar] [CrossRef]
- Rhee, C.; Klompas, M. Sepsis trends: Increasing incidence and decreasing mortality, or changing denominator? J. Thorac. Dis. 2020, 12, S89–S100. [Google Scholar] [CrossRef] [PubMed]
- Rudd, K.E.; Johnson, S.C.; Agesa, K.M.; Shackelford, K.A.; Tsoi, D.; Kievlan, D.R.; Vcolombara, D.; Sikuta, K.; Kissoon, N.; Finfer, S.; et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the Global Burden of Disease Study. Lancet 2020, 395, 200–211. [Google Scholar] [CrossRef] [Green Version]
- Rubens, M.; Saxena, A.; Ramamoorthy, V.; Das, S.; Khera, R.; Hong, J.; Armaignac, D.; Veledar, E.; Nasir, K.; Gidel, L. Increasing Sepsis Rates in the United States: Results from National Inpatient Sample, 2005 to 2014. J. Intensiv. Care Med. 2020, 35, 858–868. [Google Scholar] [CrossRef] [PubMed]
- Dugar, S.; Choudhary, C.; Duggal, A. Sepsis and septic shock: Guideline-based management. Clevel. Clin. J. Med. 2020, 87, 53–64. [Google Scholar] [CrossRef]
- Simmons, J.; Pittet, J.F. The coagulopathy of acute sepsis. Curr. Opin. Anaesthesiol. 2015, 28, 227–236. [Google Scholar] [CrossRef] [Green Version]
- Saito, S.; Uchino, S.; Hayakawa, M.; Yamakawa, K.; Kudo, D.; Iizuka, Y.; Sanui, M.; Takimoto, K.; Mayumi, T.; Sasabuchi, Y. Epidemiology of disseminated intravascular coagulation in sepsis and validation of scoring systems. J. Crit. Care 2019, 50, 23–30. [Google Scholar] [CrossRef]
- Dhainaut, J.-F.; Yan, S.B.; Joyce, D.E.; Pettila, V.; Basson, B.; Brandt, J.T.; Sundin, D.P.; Levi, M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J. Thromb. Haemost. 2004, 2, 1924–1933. [Google Scholar] [CrossRef]
- Semeraro, N.; Ammollo, C.T.; Semeraro, F.; Colucci, M. Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. Mediterr. J. Hematol. Infect. Dis. 2010, 2, e2010024. [Google Scholar] [CrossRef]
- Wang, E.; Liu, Y.; Qiu, X.; Tang, Y.; Wang, H.; Xiao, X.; Chen, F.; Lu, B. Bacteria-released outer membrane vesicles promote disseminated intravascular coagulation. Thromb. Res. 2019, 178, 26–33. [Google Scholar] [CrossRef] [PubMed]
- Iba, T.; Di Nisio, M.; Levy, J.H.; Kitamura, N.; Thachil, J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: A retrospective analysis of a nationwide survey. BMJ Open 2017, 7, e017046. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gando, S.; Shiraishi, A.; Yamakawa, K.; Ogura, H.; Saitoh, D.; Fujishima, S.; Mayumi, T.; Kushimoto, S.; Abe, T. Disseminated Intravascular Coagulation in Severe Sepsis. Chest 2019, 156, A1122. [Google Scholar] [CrossRef]
- Sarcon, A.; Liu, X.; Ton, D.; Haywood, J.; Hitchcock, T. Advanced Congestive Heart Failure Associated with Disseminated Intravascular Coagulopathy. J. Investig. Med. High Impact Case Rep. 2015, 3, 2324709615623298. [Google Scholar] [CrossRef] [Green Version]
- Ben-Ari, Z.; Osman, E.; Hutton, R.A.; Burroughs, A.K. Disseminated intravascular coagulation in liver cirrhosis: Fact or fiction? Am. J. Gastroenterol. 1999, 94, 2977–2982. [Google Scholar] [CrossRef]
- Carr, J.M. Disseminated intravascular coagulation in cirrhosis. Hepatology 1989, 10, 103–110. [Google Scholar] [CrossRef]
- Limmathurotsakul, D. Causes and outcomes of sepsis in southeast Asia: A multinational multicentre cross-sectional study. Lancet Glob. Health 2017, 5, e157–e167. [Google Scholar] [CrossRef] [Green Version]
- Koch, C.; Edinger, F.; Fischer, T.; Brenck, F.; Hecker, A.; Katzer, C.; Markmann, M.; Sander, M.; Schneck, E. Comparison of qSOFA score, SOFA score, and SIRS criteria for the prediction of infection and mortality among surgical intermediate and intensive care patients. World J. Emerg. Surg. 2020, 15, 63. [Google Scholar] [CrossRef]
- Potze, W.; Porte, R.J.; Lisman, T. Management of coagulation abnormalities in liver disease. Expert Rev. Gastroenterol. Hepatol. 2015, 9, 103–114. [Google Scholar] [CrossRef]
- Tripodi, A.; Primignani, M.; Mannucci, P.M. Abnormalities of hemostasis and bleeding in chronic liver disease: The paradigm is challenged. Intern. Emerg. Med. 2010, 5, 7–12. [Google Scholar] [CrossRef]
- Anderko, R.R.; Gómez, H.; Canna, S.W.; Shakoory, B.; Angus, D.C.; Yealy, D.M.; Huang, D.T.; Kellum, J.A.; Carcillo, J.A.; Barnato, A.E.; et al. Sepsis with liver dysfunction and coagulopathy predicts an inflammatory pattern of macrophage activation. Intensiv. Care Med. Exp. 2022, 10, 6. [Google Scholar] [CrossRef] [PubMed]
- Senzolo, M.; Burra, P.; Cholongitas, E.; Burroughs, A.-K. New insights into the coagulopathy of liver disease and liver transplantation. World J. Gastroenterol. 2006, 12, 7725–7736. [Google Scholar] [CrossRef] [PubMed]
- Ding, R.; Wang, Z.; Lin, Y.; Liu, B.; Zhang, Z.; Ma, X. Comparison of a new criteria for sepsis-induced coagulopathy and International Society on Thrombosis and Haemostasis disseminated intravascular coagulation score in critically ill patients with sepsis 3.0: A retrospective study. Blood Coagul. Fibrinolysis 2018, 29, 551–558. [Google Scholar] [CrossRef]
- Chou, E.H.; Mann, S.; Hsu, T.-C.; Hsu, W.-T.; Liu, C.C.-Y.; Bhakta, T.; Hassani, D.M.; Lee, C.-C. Incidence, trends, and outcomes of infection sites among hospitalizations of sepsis: A nationwide study. PLoS ONE 2020, 15, e0227752. [Google Scholar] [CrossRef] [Green Version]
- Purba, A.K.R.; Mariana, N.; Aliska, G.; Wijaya, S.H.; Wulandari, R.R.; Hadi, U.; Hamzah; Nugroho, C.W.; van der Schans, J.; Postma, M.J. The burden and costs of sepsis and reimbursement of its treatment in a developing country: An observational study on focal infections in Indonesia. Int. J. Infect. Dis. 2020, 96, 211–218. [Google Scholar] [CrossRef]
- Violi, F.; Cangemi, R.; Calvieri, C. Pneumonia, thrombosis and vascular disease. J. Thromb. Haemost. 2014, 12, 1391–1400. [Google Scholar] [CrossRef] [PubMed]
- Vail, G.M.; Xie, Y.J.; Haney, D.J.; Barnes, C. Biomarkers of Thrombosis, Fibrinolysis, and Inflammation in Patients with Severe Sepsis due to Community-Acquired Pneumonia with and without Streptococcus pneumoniae. Infection 2009, 37, 358–364. [Google Scholar] [CrossRef]
- Kelm, D.J.; Valerio-Rojas, J.C.; Cabello-Garza, J.; Gajic, O.; Cartin-Ceba, R. Predictors of Disseminated Intravascular Coagulation in Patients with Septic Shock. ISRN Crit. Care 2013, 2013, 219048. [Google Scholar] [CrossRef] [Green Version]
- Evans, L.; Rhodes, A.; Alhazzani, W.; Antonelli, M.; Coopersmith, C.M.; French, C.; Machado, F.R.; Mcintyre, L.; Ostermann, M.; Prescott, H.C.; et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensiv. Care Med. 2021, 47, 1181–1247. [Google Scholar] [CrossRef]
- Iba, T.; Levi, M.; Levy, J.H. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin. Thromb. Hemost. 2020, 46, 089–095. [Google Scholar] [CrossRef]
- Iba, T.; Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular coagulation; Watanabe, E.; Umemura, Y.; Wada, T.; Hayashida, K.; Kushimoto, S.; Wada, H. Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. J. Intensiv. Care 2019, 7, 32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Opal, S.M.; Girard, T.D.; Wesley Ely, E. The Immunopathogenesis of Sepsis in Elderly Patients [Internet]. Clinical Infectious Diseases. 2005, Volume 41. Available online: https://academic.oup.com/cid/article/41/Supplement_7/S504/667351 (accessed on 2 October 2022).
- Juneja, D.; Nasa, P.; Singh, O. Severe sepsis and septic shock in the elderly: An overview. World J. Crit. Care Med. 2012, 1, 23–30. [Google Scholar] [CrossRef] [PubMed]
- Pechlivani, N.; Ajjan, R.A. Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. Front. Cardiovasc. Med. 2018, 5, 135. [Google Scholar] [CrossRef] [Green Version]
- Trevelin, S.C.; Carlos, D.; Beretta, M.; da Silva, J.S.; Cunha, F.Q. Diabetes Mellitus and Sepsis A Challenging Association. Shock. 2017, 47, 276–287. [Google Scholar] [CrossRef]
- Levi, M. Disseminated Intravascular Coagulation in Cancer: An Update. Semin. Thromb. Hemost. 2019, 45, 342–347. [Google Scholar] [CrossRef]
- Papageorgiou, C.; Jourdi, G.; Adjambri, E.; Walborn, A.; Patel, P.; Fareed, J.; Elalamy, I.; Hoppensteadt, D.; Gerotziafas, G.T. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. Clin. Appl. Thromb. 2018, 24 (Suppl. S9), 8S–28S. [Google Scholar] [CrossRef] [Green Version]
- Chi, S.; Ikezoe, T. Disseminated intravascular coagulation in non-Hodgkin lymphoma. Int. J. Hematol. 2015, 102, 413–419. [Google Scholar] [CrossRef]
Variables | Developed Disseminated Intravascular Coagulation (n: 50) | Did Not Develop Disseminated Intravascular Coagulation (n: 198) |
---|---|---|
Mortality, n (%) | 38 (76%) | 133 (67.2%) |
Age, years, mean ± SD | 49.76 ± 13.97 | 55.61 ± 15.20 |
Male, n (%) | 25 (50%) | 102 (51.5%) |
Hemoglobin, g/dL, mean ± SD | 8.99 ± 2.68 | 9.83 ± 2.57 |
Anemia, n (%) | 45 (90%) | 166 (83.8%) |
Leukocyte, /mm3 median (min–max) | 16,870 (10.3–163,340) | 14,995 (6.6–98,860) |
Leukocytosis, n (%) | 39 (78%) | 154 (77.8%) |
Neutrophil/lymphocyte ratio, median (min–max) | 10.49 (0.06–91.7) | 13.39 (0.03–107.6) |
High neutrophil lymphocyte ratio, n (%) | 26 (52%) | 131 (66.2%) |
Thrombocyte, /mm3 median (min–max) | 75,500 (2000–625,000) | 246,000 (439–855,000) |
AST, U/L, median (min–max) | 45.5 (6–6859) | 38 (6–2143) |
ALT, U/L, median (min–max) | 31 (6–1632) | 23 (6–390) |
Albumin, g/dL, median (min–max) | 2.42 (1.29–4) | 2.55 (1.46–4.67) |
Albumin ≤2.5 g/dL, n (%) | 30 (60%) | 85 (42.9%) |
Ureum, mg/dL, median (min–max) | 69.15 (18–298.2) | 69.35 (7.2–251) |
Creatinine, mg/dL, median (min–max) | 1.25 (0.3–11.2) | 1.5 (0.1–15) |
eGFR, mL/min/1.73 m2 median (min–max) | 55.05 (4–170) | 48.6 (3–261) |
eGFR <60 mL/min/1.73 m2, n (%) | 26 (52%) | 113 (57.1%) |
PT, seconds, median (min–max) | 14.85 (10.1–44.2) | 12.1 (9–120) |
PTT, seconds, median (min–max) | 49.7 (29.3–180) | 41.6 (19.3–190) |
D-dimer, ng/mL, median (min–max) | 8535 (400–52,250) | 3254 (100–352,000) |
Fibrinogen, mg/dL, median (min–max) | 231.6 (38–758) | 442 (38–1044) |
Pulmonary infection, n (%) | 41 (82%) | 142 (71.7%) |
Solid cancer, n (%) | 19 (38%) | 65 (32.8%) |
Hematological cancer, n (%) | 10 (20%) | 14 (7.1%) |
Metabolic disease, n (%) | 11 (22%) | 79 (39.9%) |
Autoimmune disease, n (%) | 2 (4%) | 13 (6.6%) |
Liver disease, n (%) | 11 (22%) | 37 (18.7%) |
Heart failure, n (%) | 3 (6%) | 21 (10.6%) |
Chronic kidney disease, n (%) | 26 (52%) | 113 (57.1%) |
Received hemodialysis, n (%) | 15 (30%) | 56 (28.3%) |
Received antiplatelet, n (%) | 2 (4%) | 10 (5.1%) |
Positive Blood culture, n (%) | 11 (22%) | 44 (22.2%) |
Received antibiotic ≥ 1 h, n (%) | 39 (78%) | 124 (62.6%) |
Site of Infection | n (%) |
---|---|
Pulmonary system | 183 (73.8%) |
Gastrointestinal system | 20 (8.1%) |
Hepatobiliary system | 10 (4%) |
Nervous system | 2 (0.8%) |
Reproductive system | 1 (0.4%) |
Kidney and urinary system | 11 (4.4%) |
Soft tissue | 21 (8.5%) |
Hematological Cancer Type | n (%) |
---|---|
AML | 5 (20.8%) |
ALL | 1 (4.2%) |
CML | 2 (8.3%) |
CLL | 0 (0%) |
Myeloproliferative neoplasm | 1 (4.2%) |
Hodgkin’s lymphoma | 2 (8.3%) |
Non-Hodgkin’s lymphoma | 10 (417%) |
Multiple myeloma | 3 (12.5%) |
Variables | Odds Ratio | 95% Confidence Interval | p-Value |
---|---|---|---|
Male | 0.941 | 0.506–1.750 | 0.848 |
Female | Reference | ||
Age ≥60 years | 0.467 | 0.234–0.933 | 0.031 |
Age <60 years | Reference | ||
Respiratory infection | 1.797 | 0.819–3.939 | 0.144 |
No respiratory infection | Reference | ||
Solid cancer | 1.254 | 0.659–2.387 | 0.490 |
No solid cancer | Reference | ||
Hematological cancer | 3.286 | 1.362–7.926 | 0.008 |
No hematological cancer | Reference | ||
Metabolic disease | 0.425 | 0.205–0.879 | 0.021 |
No metabolic disease | Reference | ||
Albumin ≤2.5 g/dL | 1.994 | 1.060–3.751 | 0.032 |
Albumin >2.5 g/dL | Reference | ||
Liver disease | 1.227 | 0.575–2.621 | 0.597 |
No liver disease | Reference | ||
Autoimmune disorder | 0.593 | 0.129–2.717 | 0.501 |
No autoimmune disease | Reference | ||
Heart failure | 0.538 | 0.154–1.881 | 0.332 |
No heart failure | Reference | ||
eGFR <60 mL/min/1.73 m2 | 0.815 | 0.437–1.518 | 0.519 |
eGFR ≥60 mL/min/1.73 m2 | Reference | ||
Chronic kidney disease | 0.815 | 0.437–1.518 | 0.519 |
No chronic kidney disease | Reference | ||
Received hemodialysis | 1.087 | 0.551–2.144 | 0.810 |
Did not receive hemodialysis | Reference | ||
Received antiplatelet | 0.783 | 0.166–3.694 | 0.758 |
Did not receive antiplatelet | Reference | ||
Anemia | 1.735 | 0.639–4.709 | 0.279 |
No anemia | Reference | ||
Leukocytosis | 1.013 | 0.479–2.141 | 0.973 |
No leukocytosis | Reference | ||
High neutrophil lymphocyte ratio | 0.554 | 0.296–1.038 | 0.065 |
Low neutrophil lymphocyte ratio | Reference | ||
Positive blood culture | 0.987 | 0.467–2.086 | 0.973 |
Negative blood culture | Reference | ||
Received antibiotic ≥1 h | 2.116 | 1.021–4.384 | 0.044 |
Received antibiotic <1 h | Reference |
Variables | Odds Ratio | 95% Confidence Interval | p-Value |
---|---|---|---|
Age ≥60 years | 0.523 | 0.247–1.107 | 0.090 |
Age <60 years | Reference | ||
Albumin ≤2.5 g/dL | 2.363 | 1.201–4.649 | 0.013 |
Albumin >2.5 g/dL | Reference | ||
Respiratory infection | 2.414 | 1.046–5.571 | 0.039 |
No respiratory infection | Reference | ||
Metabolic disease | 0.485 | 0.224–1.051 | 0.067 |
No metabolic disease | Reference | ||
Received antibiotic ≥1 h | 2.181 | 1.014–4.689 | 0.046 |
Received antibiotic <1 h | Reference |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rinaldi, I.; Sudaryo, M.K.; Prihartono, N.A. Disseminated Intravascular Coagulation in Sepsis and Associated Factors. J. Clin. Med. 2022, 11, 6480. https://doi.org/10.3390/jcm11216480
Rinaldi I, Sudaryo MK, Prihartono NA. Disseminated Intravascular Coagulation in Sepsis and Associated Factors. Journal of Clinical Medicine. 2022; 11(21):6480. https://doi.org/10.3390/jcm11216480
Chicago/Turabian StyleRinaldi, Ikhwan, Mondastri Korib Sudaryo, and Nurhayati Adnan Prihartono. 2022. "Disseminated Intravascular Coagulation in Sepsis and Associated Factors" Journal of Clinical Medicine 11, no. 21: 6480. https://doi.org/10.3390/jcm11216480